Sökning: onr:"swepub:oai:DiVA.org:liu-131707" > Levodopa-carbidopa ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05765naa a2200553 4500 | |
001 | oai:DiVA.org:liu-131707 | |
003 | SwePub | |
008 | 160930s2016 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:134148541 | |
009 | oai:DiVA.org:uu-300787 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1317072 URI |
024 | 7 | a https://doi.org/10.1016/j.parkreldis.2016.06.0022 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1341485412 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3007872 URI |
040 | a (SwePub)liud (SwePub)kid (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Pålhagen, Sven E.u Karolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden4 aut |
245 | 1 0 | a Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinsons disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs |
264 | 1 | b ELSEVIER SCI LTD,c 2016 |
338 | a electronic2 rdacarrier | |
500 | a Funding Agencies|AbbVie Inc. | |
520 | a Background: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinsons disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG. Methods: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naive (N = 37), or had previous LCIG treatment for amp;lt;2 (N = 22), or amp;gt;= 2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinsons Disease Rating Scale (UPDRS), 39-item Parkinsons Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were monitored. Results: Mean monthly costs per patient ( 8226 5952) were similar across cohorts, remained steady during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naive patients, significant improvements compared to baseline were observed on the UPDRS total score and PDQ-39 summary index score through 18 months (n = 24; UPDRS, p = 0.033; PDQ-39, p = 0.049). Symptom control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean daily LCIG dose were observed. Adverse events were common and generally related to the device, procedure, levodopa, or laboratory evaluations. Conclusions: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to significant improvements in motor function and QoL over 18 months in LCIG-naive patients and no worsening was observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The longterm safety was consistent with the established LCIG profile. (C) 2016 AbbVie Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a Parkinsons disease; Levodopa; Infusion; LCIG; Cost | |
700 | 1 | a Sydow, Olofu Karolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden4 aut |
700 | 1 | a Johansson, Andersu Uppsala universitet,Karolinska Institutet,Neurologi4 aut0 (Swepub:uu)andejoha |
700 | 1 | a Nyholm, Dagu Uppsala universitet,Neurologi4 aut0 (Swepub:uu)danyh856 |
700 | 1 | a Holmberg, Bjornu Sahlgrens University Hospital, Sweden,Sahlgrens Univ Hosp, Dept Clin Neurosci, Gothenburg, Sweden4 aut |
700 | 1 | a Widner, Hakanu Skåne University Hospital, Sweden,Skane Univ Hosp, Dept Neurol, Lund, Sweden4 aut |
700 | 1 | a Dizdar Segrell, Nilu Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linkoping Univ, Dept Neurol, Linkoping, Sweden; Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden4 aut0 (Swepub:liu)nildi39 |
700 | 1 | a Linder, Janu Norrlands University Hospital, Sweden,Norrlands Univ Hosp, Neuroctr, Dept Neurol, Umea, Sweden4 aut |
700 | 1 | a Hauge, Toveu Molde Hospital HNR, Norway,Molde Hosp HNR, Dept Neurol, Molde, Norway4 aut |
700 | 1 | a Jansson, Rasmusu Sundsvall Hospital, Sweden,Sundsvall Hosp, Dept Geriatr Med & Rehabil, Sundsvall, Sweden4 aut |
700 | 1 | a Bergmann, Larsu AbbVie Inc, N Chicago, IL USA4 aut |
700 | 1 | a Kjellander, Susannau AbbVie AB, Solna, Sweden4 aut |
700 | 1 | a Marshall, Thomas S.u AbbVie Inc, N Chicago, IL USA4 aut |
710 | 2 | a Karolinska University Hospital, Swedenb Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden4 org |
773 | 0 | t Parkinsonism & Related Disordersd : ELSEVIER SCI LTDg 29, s. 17-23q 29<17-23x 1353-8020x 1873-5126 |
856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:1010256/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u http://www.prd-journal.com/article/S1353802016301985/pdf |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:952448/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-131707 |
856 | 4 8 | u https://doi.org/10.1016/j.parkreldis.2016.06.002 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:134148541 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300787 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.